Questions to the Committee

In this guide

In this guide

- 1. Background and Introduction Garcinia cambogia oral consumption
- 2. Data from authoritative bodies Garcinia cambogia oral consumption
- 3. Chemical composition Garcinia cambogia oral consumption
- 4. ANSES Garcinia cambogia oral consumption
- 5. AESAN Garcinia cambogia oral consumption
- 6. Australian TGA Garcinia cambogia oral consumption
- 7. <u>BfR (German Federal Institute for Risk Assessment) Garcinia cambogia oral</u> consumption
- 8. EFSA Garcinia cambogia oral consumption
- 9. Health Canada Garcinia cambogia oral consumption
- 10. NCCIH Garcinia cambogia oral consumption
- 11. Data from literature search Garcinia cambogia oral consumption
- 12. Human data Garcinia cambogia oral consumption
- 13. Hepatotoxic case reports Garcinia cambogia oral consumption
- 14. Animal studies Garcinia cambogia oral consumption
- 15. Exposure Garcinia cambogia oral consumption
- 16. Uncertainties Garcinia cambogia oral consumption
- 17. Risk Characterisation Garcinia cambogia oral consumption
- 18. Questions to the Committee Garcinia cambogia oral consumption
- 19. Abbreviations Garcinia cambogia oral consumption
- 20. References Garcinia cambogia oral consumption

This is a discussion paper. It does not reflect the views of the Committee. It should not be cited.

- 198. The Committee are asked to consider the following questions:
- a) Does the Committee agree with the conclusions reached by ANSES?

- b) Based on the current data, is the Committee able to identify a no-observed effect level or any other options, to derive a health-based guidance value?
- i) If no, what additional information would the Committee require to provide a risk assessment?
- c) Does the Committee have any other comments?

October 2025

Secretariat